从2026年1月1日起,康涅狄格州将非专利药物价格大幅上涨作为上限,以降低成本,节省数百万人。 Connecticut caps generic drug price hikes at inflation starting Jan. 1, 2026, to lower costs and save millions.

自2026年1月1日起,康涅狄格州成为第一个在通胀时限制非专利药物价格上涨的州,目的是降低各类保险居民的费用。 Connecticut became the first state to cap generic drug price increases at inflation starting January 1, 2026, aiming to lower costs for residents across all insurance types. 这项法律得到内德·拉蒙特州长和马特·莱瑟州参议员的支持,第一年可节省1 050万美元,全国可节省多达15亿美元,用于医疗保险受益者。 The law, backed by Governor Ned Lamont and State Senator Matt Lesser, could save $10.5 million in its first year and up to $1.5 billion nationally for Medicare beneficiaries. 违反者面临高达超额利润80%的罚款,并计划提交年度执法报告。 Violators face fines up to 80% of excess profits, with annual enforcement reports planned. 虽然美国农业协会和州官员赞扬该措施,但包括PhRMA和一些立法者在内的批评者警告说,它可能会损害药物创新,并建议专注于PBM或批量采购. While AARP and state officials praise the measure, critics including PhRMA and some lawmakers warn it may harm drug innovation and suggest focusing on PBMs or bulk purchasing.